Sodium oxybate in narcolepsy with cataplexy: Zurich sleep center experience

European Neurology

Volumn 65, Issue 3, 2011, Pages 175-182

  Poryazova, R ^a   Tartarotti, S ^a   Khatami, R ^b   Baumann, C R ^a   Valko, P ^a   Kallweit, U ^a   Werth, E ^a   Bassetti, C L ^a,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Sleep Clinic   (Switzerland)

^c Ospedale Civico Lugano   (Switzerland)

Author keywords

Cataplexy; Excessive daytime sleepiness; Hallucinations; Narcolepsy; Sleep paralysis; Sodium oxybate

Indexed keywords

CENTRAL STIMULANT AGENT; CLOMIPRAMINE; FLUOXETINE; HLA DQB1 ANTIGEN; METHYLPHENIDATE; MODAFINIL; OREXIN; OXYBATE SODIUM; VENLAFAXINE;

ACTIMETRY; ADD ON THERAPY; ADULT; AGED; ARTICLE; ATTENTION; BEDTIME DOSAGE; CATAPLEXY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENURESIS; EPWORTH SLEEPINESS SCALE; FEMALE; FLATULENCE; HALLUCINATION; HUMAN; MAINTENANCE OF WAKEFULNESS TEST; MALE; MONOTHERAPY; MULTIPLE SLEEP LATENCY TEST; MYALGIA; NARCOLEPSY; NAUSEA; NIGHTTIME CONFUSION; PARASOMNIA; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; REM SLEEP; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP; SOMNOLENCE; STEER CLEAR TEST;

ACTIGRAPHY; ADOLESCENT; ADULT; AGED; CATAPLEXY; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOLEPSY; POLYSOMNOGRAPHY; SODIUM OXYBATE; TREATMENT OUTCOME;

EID: 79952351825     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000324549     Document Type: Article

References (36)

1. Bassetti C, Aldrich MS: Narcolepsy. Neurol Clin 1996; 14: 545-571. (Pubitemid 26269992)
2. American Academy of Sleep Medicine (AASM): International Classification of Sleep Disorders. Diagnostic and Coding Manual, ed 2. Westchester/IL, AASM, 2005.
3. Lin L, Hungs M, Mignot E: Narcolepsy and the HLA region. J Neuroimmunol 2001; 117: 9-20. (Pubitemid 32595489)
4. Mignot E, Lammers GJ, Ripley B, et al: The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002; 59: 1553-1562.
5. Billiard M: Narcolepsy: current treatment options and future approaches. Neuropsychiatr Dis Treat 2008; 4: 557-666.
6. Vayer P, Mandel P, Maitre M: γ -Hydroxybutyrate, a possible neurotransmitter. Life Sci 1987; 41: 1547-1557.
7. Snead OC, Liu C: γ -Hydroxybutyric acid binding sites in rat and human brain synaptosomal membranes. Biochem Pharmacol 1984; 33: 2587-2590. (Pubitemid 14098777)
8. Yamada Y, Yamamoto J, Fujiki A, Hishakawa Y, Kaneko Z: Effect of butyrolactone andγ - hydroxybutyrate on the EEG and sleep cycle in man. Electroencephalogr Clin Neurophysiol 1967; 22: 558-562.
9. Broughton R, Mamelak M: In Guilleminault C, Dement WC, Passousant P (eds): Advances in Sleep Research. New York, Spectrum, 1976, pp 659-667.
10. Broughton R, Mamelak M: The treatment of narcolepsy-cataplexy with nocturnalγ -hydroxybutyrate. Can J Neurol Sci 1979; 6: 1-6.
11. Scharf M, Brown D, Woods M, et al: The effects and effectiveness ofγ -hydroxybutyrate in patients with narcolepsy. J Clin Psychiatry 1985; 46: 222-225. (Pubitemid 15093425)
12. Scrima L, Hartman PG, Johnson FH Jr, Hiller FC: Efficacy ofγ -hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 1989; 26: 331-343. (Pubitemid 19198218)
13. Lammers GJ, Arends J, Declerck AC, et al: -Hydroxybutyrate and narcolepsy: a double- blind placebo-controlled study. Sleep 1993; 6: 216-220. (Pubitemid 23119044)
14. Takahara J, Younuki S, Yakushiji W: Stimulatory effects of- -hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab 1977; 44:1014-1016.
15. Herbrand R, Greminger P, Schurter G, Pletscher W, Kupferschmidt H: Sudden coma in a 20-year-old man (in German). Praxis (Bern 1994) 2000; 89: 1326-1330. (Pubitemid 30662052)
16. Liechti ME, Kupferschmidt H: γ -Hydroxybutyrate (GHB) and- -butyrolactone (GBL): analysis of overdose cases reported to the Swiss Toxicological Information Centre. Swiss Med Wkly 2004; 134: 534-537. (Pubitemid 39389966)
17. Iten PX, Oestreich A, Lips R, Brabetz M: A new drug reaches Switzerland: coma after intake of- -hydroxybutyrate (GHB) (in German). Schweiz Med Wochenschr 2000; 130: 356-361. (Pubitemid 30154839)
18. Bundesamt f̈r Gesundheit BAG. Factsheet GHB 2009.
19. Zvosec DL, Smith SW, Hall BJ: Three deaths associated with use of Xyrem® . Sleep Med 2009; 10: 490-493.
20. Lammers GJ, Bassetti C, Billiard M et al: Sodium oxybate is an effective and safe treatment for narcolepsy. Sleep Med 2010; 11: 105-106.
21. US Xyrem®Multicenter Study Group: A randomized, double-blind, placebo-controlled multi-center trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25: 42-49.
22. US Xyrem®Multicenter Study Group: Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004; 5: 119-123.
23. US Xyrem®Multicenter Study Group: A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003; 1: 31-35.
24. Mamelak M, Black J, Montplaisir J, Ristanovic R: A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004; 27: 1327-1334. (Pubitemid 44138899)
25. Xyrem®International Study Group: Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a doubleblind, placebo-controlled study in 228 patients. Sleep Med 2005; 6: 415-421.
26. Black J, Houghton WC: Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006; 29: 939-946.
27. Xyrem International Study Group: A doubleblind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005; 1: 391-397.
28. Billiard M, Bassetti C, Dauvilliers Y, et al: EFNS guidelines on management of narcolepsy. Eur J Neurol 2006; 13: 1035-1048. (Pubitemid 44434309)
29. Rechtschaffen A, Kales A: A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of human Subjects. Los Angeles, UCLA Brain Information Service/Brain Research Institute, 1968.
30. American Sleep Disorders Association: EEG arousals: scoring rules and examples. A preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992; 15: 174-184.
31. American Academy of Sleep Medicine Task Force: Sleep-disordered breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep 1999; 22; 667-688.
32. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S: Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986; 9: 519-524. (Pubitemid 17131209)
33. Findley L, Unverzagt M, Guchu R, Fabrizio M, Buckner J, Suratt P: Vigilance and automobile accidents in patients with sleep apnea or narcolepsy. Chest 1995; 108: 619-624.
34. Mamelak M, Scharf MB, Woods M: Treatment of narcolepsy withγ -hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 1986; 9: 285-289. (Pubitemid 18008511)
35. George CF, Feldman N, Zheng Y, Steininger TL, Grzeschik SM, Lai C, Inhaber N: A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome. Sleep Breath (in press).
36. Black J, Pardi D, Hornfeldt CS, Inhaber N: The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med 2009; 10: 829-835.